Samarium (¹⁵³Sm) lexidronam

Samarium (¹⁵³Sm) lexidronam
Clinical data
Trade names	Quadramet
Routes of; administration	Intravenous
ATC code	V10BX02 (WHO) ;
Legal status
Legal status	EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	N/A
Identifiers
	IUPAC name Pentasodium samarium (153Sm) N,N,N',N'-tetrakis(phosphonatomethyl)ethane-1,2-diamine;
CAS Number	122575-21-7 ; 176669-18-4 (pentasodium);
PubChem CID	9810246;
UNII	745X144DZY;
ChEMBL	ChEMBL1201796;
CompTox Dashboard (EPA)	DTXSID30936282 ;
Chemical and physical data
Formula	C6H12N2Na5O12P4153Sm
Molar mass	695.93 g/mol
3D model (JSmol)	Interactive image; covalent form: Interactive image;
	SMILES C(CN(CP(=O)([O-])[O-])CP(=O)([O-])[O-])N(CP(=O)([O-])[O-])CP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[153Sm+3]; ; covalent form: C(CN(CP(=O)([O-])O[153Sm-]123)CP(=O)([O-])O1)N(CP(=O)([O-])O2)CP(=O)([O-])O3.[Na+].[Na+].[Na+].[Na+].[Na+];

Samarium (¹⁵³Sm) lexidronam (chemical name Samarium-153-ethylene diamine tetramethylene phosphonate, abbreviated Samarium-153 EDTMP, trade name Quadramet) is a chelated complex of a radioisotope of the element samarium with EDTMP. It is used to treat pain when cancer has spread to the bone.^[1]^[2]

It is injected into a vein and distributed throughout the body, where it is preferentially absorbed in areas where cancer has invaded the bone. The radioisotope ¹⁵³Sm, with a half-life of 46.3 hours, decays by emitting beta particles (electrons), which kill the nearby cells. Pain begins to improve in the first week for most people and the effects can last several months. It is commonly used in lung cancer, prostate cancer, breast cancer, and osteosarcoma.

Side effects

Side effects^[3] include the following:

Black, tarry stools
Blood in urine/stool
Cough, hoarseness
Fever/chills
Lower back/side pain
Painful or difficult urination
Pinpoint red spots on skin
Irregular heartbeat
Nausea, vomiting

Supply and administration

Samarium lexidronam is supplied as a frozen solution for intravenous use with an activity of 50±5 mCi/mL^[4] and a maximum beta energy of 0.808 MeV.^[5] Due to the short half-life of the radioisotope, the drug expires 56 hours after the noted calibration time.^[4]

References

^ Anderson P (August 2006). "Samarium for osteoblastic bone metastases and osteosarcoma". Expert Opinion on Pharmacotherapy. 7 (11): 1475–86. doi:10.1517/14656566.7.11.1475. PMID 16859431. S2CID 36773109.
^ Finlay IG, Mason MD, Shelley M (June 2005). "Radioisotopes for the palliation of metastatic bone cancer: a systematic review". The Lancet. Oncology. 6 (6): 392–400. doi:10.1016/S1470-2045(05)70206-0. PMID 15925817.
^ "Quadramet Side Effects in Detail". Drugs.com.
^ ^a ^b FDA Professional Drug Information on Quadramet. 2009.
^ Bé M, Coursol N, Duchemin B, Lagoutine F, Legrand J. "Table of Radionuclides" (PDF). Henry Becquerel National Laboratory. Archived from the original (PDF) on 17 July 2019. Retrieved 22 April 2020.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[pmid16859431-1] Anderson P (August 2006). "Samarium for osteoblastic bone metastases and osteosarcoma". Expert Opinion on Pharmacotherapy. 7 (11): 1475–86. doi:10.1517/14656566.7.11.1475. PMID 16859431. S2CID 36773109.

[pmid15925817-2] Finlay IG, Mason MD, Shelley M (June 2005). "Radioisotopes for the palliation of metastatic bone cancer: a systematic review". The Lancet. Oncology. 6 (6): 392–400. doi:10.1016/S1470-2045(05)70206-0. PMID 15925817.

[side_effects-3] "Quadramet Side Effects in Detail". Drugs.com.

[drugs.com-4] FDA Professional Drug Information on Quadramet. 2009.

[5] Bé M, Coursol N, Duchemin B, Lagoutine F, Legrand J. "Table of Radionuclides" (PDF). Henry Becquerel National Laboratory. Archived from the original (PDF) on 17 July 2019. Retrieved 22 April 2020.

[1]

[2]

[3]

[4]

[5]